Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

Ponatinib

0bf6b54d-2eec-5def-b516-2c059f638222 · FDA Approved · targets BCR_ABL, ABL1, ABL2_ARG

Ponatinib

MeasuredReference

Ponatinib targets ABL1, ABL2_ARG, BLK. Strongest hallmark effect: tumor promoting inflammation.

Top hallmarks

  • tumor promoting inflammation7.5k
  • proliferation5.6k
  • evading apoptosis5.5k

Top pathways disrupted

  • pi3k akt mtor signaling14.1k
  • apical junction13.7k
  • allograft rejection12.4k

Resistance landscape — Ponatinib

MeasuredReference

10 known oncogenic variants exist on Ponatinib's top targets — see detail for inhibition impact.

Open in new tab